Meriofert

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as a sterile injectable solution for intramuscular and subcutaneous use. It treats infertility due to anovulation and is used for controlled ovarian stimulation in assisted reproductive technologies.

GNH USA supplies Meriofert as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert is a gonadotropin used in reproductive medicine to support follicular development and ovulation. - Infertility due to anovulation: supports follicular growth to enable ovulation. - Controlled ovarian stimulation for assisted reproductive technologies: provides exogenous FSH and LH to synchronize multiple follicle development. - Ovulation induction in polycystic ovary syndrome: facilitates ovulation when endogenous gonadotropins are insufficient.

Common Side Effects: - Injection site reactions: pain, redness, or swelling at the injection site. - Mild abdominal discomfort or pelvic pain. - Headache. - Nausea.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid ovarian enlargement, fluid shift, and thromboembolic risk. - Multiple pregnancy: increased chance of twins or higher order gestations. - Allergic reactions: rash, urticaria, or anaphylaxis. - Ectopic pregnancy. - Severe abdominal pain indicating possible ovarian torsion.

Before initiating therapy, clinicians should consider several safety measures. - Monitor ovarian response: use ultrasound and estradiol levels to adjust dosing. - Avoid use in known hypersensitivity: discontinue if allergic signs appear. - Assess for ovarian cysts: contraindicated if active cysts are present. - Consider risk of multiple pregnancy: counsel patients on potential outcomes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other medications affecting ovarian function.

Major Interactions (Avoid): - GnRH agonists: can amplify ovarian response, increasing hyperstimulation risk. - Oral contraceptives: suppress endogenous gonadotropins, reducing efficacy. - Chemotherapy agents: may impair ovarian function, altering response.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may affect ovarian response; monitor thyroid status. - Anticoagulants: increased risk of ovarian bleeding; monitor coagulation parameters. - Corticosteroids: may alter hormone metabolism; observe clinical response.